The Latest in Leukemia, Myelodysplasia, Transplantation

Company withdraws MAA for biosimilar pegfilgrastim

December 29, 2016

FDA places AML trials on full, partial clinical hold

December 28, 2016

Combo produces high response rate in CLL trial

December 24, 2016

KTE-C19 feasible in most young, high-risk ALL patients, study suggests

December 23, 2016

Intermittent fasting fights ALL, not AML, in mice

December 21, 2016

Ruxolitinib may prevent CRS after CAR T-cell therapy

December 20, 2016

Leukemia, Myelodysplasia, Transplantation

Combo improves ORR, PFS in relapsed/refractory CLL

December 19, 2016

MDS patients with mutated IDH2 benefit from enasidenib

December 19, 2016

CHMP recommends authorization of rituximab biosimilar

December 18, 2016

Congenital CMV linked to increased risk of ALL

December 16, 2016

Platform could optimize treatment of ALL, other diseases

December 15, 2016

Study reveals CML patients likely to benefit from HSCT long-term

December 15, 2016

EC authorizes new use for ofatumumab in CLL

December 14, 2016

Two mutations may help drive CBF-AML

December 14, 2016

How old is too old to be on a kids’ protocol for ALL?

December 14, 2016